Rocket PharmaceuticalsRCKT
RCKT
About: Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
Employees: 268
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
258% more call options, than puts
Call options by funds: $4.96M | Put options by funds: $1.39M
65% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 20
19% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 54
7% more funds holding
Funds holding: 178 [Q2] → 190 (+12) [Q3]
0.28% more ownership
Funds ownership: 102.06% [Q2] → 102.34% (+0.28%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]
14% less capital invested
Capital invested by funds: $1.99B [Q2] → $1.72B (-$277M) [Q3]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$29
185%
upside
Avg. target
$49
377%
upside
High target
$65
540%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Jefferies Andrew Tsai 0% 1-year accuracy 0 / 5 met price target | 185%upside $29 | Buy Initiated | 18 Dec 2024 |
Canaccord Genuity Whitney Ijem 18% 1-year accuracy 7 / 40 met price target | 284%upside $39 | Buy Maintained | 19 Nov 2024 |
Leerink Partners Mani Foroohar 24% 1-year accuracy 4 / 17 met price target | 333%upside $44 | Outperform Maintained | 19 Nov 2024 |
Cantor Fitzgerald Josh Schimmer 37% 1-year accuracy 22 / 59 met price target | 540%upside $65 | Overweight Reiterated | 19 Nov 2024 |
Needham Gil Blum 15% 1-year accuracy 26 / 169 met price target | 412%upside $52 | Buy Reiterated | 19 Nov 2024 |
Financial journalist opinion
Based on 3 articles about RCKT published over the past 30 days
Negative
Zacks Investment Research
6 days ago
Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Rocket Pharmaceuticals (RCKT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Positive
Benzinga
2 weeks ago
Top 3 Health Care Stocks That Could Blast Off This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Neutral
Business Wire
2 weeks ago
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, in San Francisco, California. Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present on Monday, January 13, at 3:45 p.m. PT and host investor meetings throu.
Positive
Investopedia
1 month ago
Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'
Shares of Rocket Pharmaceuticals (RCKT) jumped 5.5% intraday Wednesday as Jefferies initiated coverage of the biotech company with a "buy" rating on optimism about the experimental drugs in its pipeline. Jefferies also set a price target of $29, more than double its current value.
Neutral
Business Wire
1 month ago
Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced today the pricing of an upsized underwritten public offering of 13,200,000 shares of its common stock at a public offering price of $12.50 per share. The gross proceeds to Rocket from the offering, before deducting underwriting discounts and commissions and offer.
Neutral
Business Wire
1 month ago
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced today that it intends to offer and sell $150 million of shares of its common stock in an underwritten public offering. In addition, Rocket intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of shares of its common stock o.
Positive
MarketBeat
1 month ago
3 Small-Cap Stocks That Are Ready to Rocket Higher
The Russell 2000 Index, often called the small-cap index, is up about 19.6% in 2024. Much of that gain has come in the last six months, and the clarity after the U.S. presidential election is stirring animal spirits in the sector.
Neutral
Business Wire
1 month ago
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 7th Annual Evercore HealthCONx Conference in Miami, Florida. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat on Tuesday, December 3, at 1:45 p.m. ET and host investor meetings throughout.
Positive
Benzinga
2 months ago
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst
On Monday, Rocket Pharmaceuticals, Inc. RCKT presented long-term safety and efficacy results from the Phase 1 study of RP-A501 in male patients with Danon disease.
Neutral
Business Wire
2 months ago
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, presented long-term safety and efficacy results from the Phase 1 RP-A501 study which showed that RP-A501 was generally well tolerated and all evaluable Danon disease patients demonstrated LAMP2 protein expression at 12 months (sustained up to 60 months) and reduction of le.
Charts implemented using Lightweight Charts™